ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 10ÔÂ23ÈÕ£¬£¬£¬£¬¾ÝCDE¹ÙÍøÏÔʾ£¬£¬£¬£¬ÉñÖÝϸ°û¹¤³ÌÓÐÏÞ¹«Ë¾µÄÔ¤·ÀÓÃÉúÎïÖÆÆ·1.2ÀàÐÂÒ©SCTV02×¢ÉäÒº»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬£¬Ë³Ó¦Ö¢ÎªÔ¤·ÀºôÎüµÀºÏ°û²¡¶¾£¨RSV£©Ñ¬È¾ÒýÆðµÄ¼²²¡¡£¡£¡£
2. 10ÔÂ22ÈÕ£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬Õý´óÌìÇçÁ½¿î1ÀàÐÂÒ©»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬£¬Ë³Ó¦Ö¢ÎªTQB3616½ºÄÒÁªºÏTQB3912ƬºÍ·úά˾ȺעÉäÒº£¬£¬£¬£¬ÓÃÓÚÖÎÁÆÍíÆÚHRÑôÐÔ¡¢HER2ÒõÐÔÈéÏÙ°©¡£¡£¡£TQB3616£¨¿âĪÎ÷Àû½ºÄÒ£¬£¬£¬£¬culmerciclib£©ÊÇÒ»ÖÖCDK2/4/6ÒÖÖÆ¼Á£¬£¬£¬£¬TQB3912ÊÇÒ»ÖÖAKTÒÖÖÆ¼Á¡£¡£¡£
3. ¿ËÈÕ£¬£¬£¬£¬°¬¶ûÆÕÔÙÉúҽѧ×ÔÖ÷Ñз¢µÄÐÂÒ»´úϸ°ûÁÆ·¨¡°ÈËiPSCȪԴÐļ¡Ï¸°û×¢ÉäÒº¡±£¨HiCM - 188£©Õýʽ»ñÅúFDA£¬£¬£¬£¬ÊÇÊ׸öÔÚÃÀ¹ú½ÓÊÜÓÃÓÚÖÎÁÆÖÕÄ©ÆÚÐÄÁ¦Ë¥½ßÁÙ´²ÆÀ¹ÀµÄ iPSC ÑÜÉúϸ°ûÁ¢ÒìÒ©£¬£¬£¬£¬Ò²ÊÇÆù½ñÈ«ÇòÊ×¼ÒÔÚÖÐÃÀͬʱ»ñµÃ IND ×¢²áµÄÐÄ˥ϸ°ûÒ©Æ·¡£¡£¡£
4. 10ÔÂ21ÈÕ£¬£¬£¬£¬¿µ¶÷±´Í¨¸æ£¬£¬£¬£¬¹«Ë¾ÊÕµ½¹ú¼ÒÒ©¼à¾ÖÅú׼ǩ·¢µÄZY13ÌáÈ¡ÎPƬµÄ¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡·£¬£¬£¬£¬Ë³Ó¦Ö¢ÎªÒõÐé»ðÍúËùÖµÄÄêËêÏà¹ØÐԻư߱äÐÔ£¬£¬£¬£¬¸øÒ©Í¾¾¶Îª¿Ú·þ¸øÒ©£¬£¬£¬£¬×¢²á·ÖÀàÊôÖÐÒ©1.2ÀàÐÂÒ©¡£¡£¡£
1. 10ÔÂ22ÈÕ£¬£¬£¬£¬±±¾©¾¼Ã¼¼Êõ¿ª·¢ÇøÓëÉϺ£¸´ÐÇÒ½Ò©£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾Ç©ÊðÕ½ÂÔÏàÖú¿ò¼ÜÐÒ飬£¬£¬£¬±ê¼Ç×ÅË«·½ÔÚÉúÎï¼¼ÊõºÍ´ó¿µ½¡ÁìÓòµÄÉî¶ÈÏàÖúÕýʽÆô¶¯¡£¡£¡£´Ë´ÎÏàÖú½«ÔÚÈ«Çò¹æÄ£ÄÚÍÆ¶¯¿Æ¼¼Á¢ÒìºÍ¹¤ÒµÉý¼¶£¬£¬£¬£¬Öصã¾Û½¹Ò©Ðµ²úÆ·µÄÑз¢¡¢Éú²ú¡¢ÏúÊÛÈ«¹¤ÒµÁ´Ìõ¡£¡£¡£
1. 10ÔÂ18ÈÕ£¬£¬£¬£¬ÖÐɽ´óѧ³Â½£»£»£»£»Ô½ÌÊÚÑо¿ÍŶÓÔÚÆÚ¿¯¡¶Cell Death&Disease¡·ÉϽÒÏþÁËÌâΪ¡°Tumor-secreted LCN2 impairs gastric cancer progression via autocrine inhibition of the 24p3R/JNK/c-Jun/SPARC axis¡±µÄÑо¿ÂÛÎÄ£¬£¬£¬£¬±¾Ñо¿Ö¼ÔÚ̽ÌÖLCN2ÔÚθ°©Ï£ÍûÖеĹ¦Ð§×÷Óü°Æäµ÷¿Ø»úÖÆ¡£¡£¡£ÕâЩ·¢Ã÷Åú×¢£¬£¬£¬£¬LCN2/24p3R/JNK/c-Jun/SPARCÖáÔÚθ°©µÄ¶ñÐÔÏ£ÍûÖÐÆð×ÅÒªº¦×÷Ó㬣¬£¬£¬ÌṩÁËеÄÔ¤ºó±ê¼ÇÎïºÍÖÎÁưе㡣¡£¡£
[1]Huang, Z., Li, Y., Qian, Y. et al. Tumor-secreted LCN2 impairs gastric cancer progression via autocrine inhibition of the 24p3R/JNK/c-Jun/SPARC axis. Cell Death Dis 15, 756 (2024). https://doi.org/10.1038/s41419-024-07153-z
Ïà¹ØÐÂÎÅ